Episode 18. Management of Smoldering Multiple Myeloma

Blood Cancer Talks

İçerik Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

1+ y ago 46:32

MP3•Bölüm sayfası

1. How I Approach Smoldering Myeloma (Vaxman and Gertz):

https://ashpublications.org/blood/article/140/8/828/485274

2. Risk-Stratification Models in SMM:

Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/

PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/

PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/

IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/

3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):

https://pubmed.ncbi.nlm.nih.gov/36067617/

4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):

https://pubmed.ncbi.nlm.nih.gov/31652094/

5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:

GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268

ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739

6. Current Clinical Trial Landscape in Smoldering Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34114943/

7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?

https://pubmed.ncbi.nlm.nih.gov/35190659/

52 bölüm

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff